CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?

Indian Heart Journal

Volumn 64, Issue 4, 2012, Pages 341-352

  Singh, Mukesh ^a   Shah, Tejaskumar ^a   Adigopula, Sasikanth ^a   Molnar, Janos ^a   Ahmed, Aziz ^a   Khosla, Sandeep ^a   Arora, Rohit ^a  

^a The Chicago Medical College   (United States)

Author keywords

ABCB1 C3435T polymorphisms; CYP2C19*2 polymorphisms; Genetic testing

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METOPROLOL; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC SCREENING; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; QUALITY CONTROL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STENT THROMBOSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; GENETICS; HETEROZYGOTE; THROMBOCYTE AGGREGATION;

ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HETEROZYGOTE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84870759867     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ihj.2012.06.003     Document Type: Article

References (52)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113(19): 2363-2372.
2. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358(9281): 527-533.
3. Chen ZM, Jiang LX, Chen YP, et al COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366(9497): 1607-1621.
4. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs; a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009; 30: 426-435.
5. Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hypo responsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag. 2009; 5: 965-972.
6. Gurbel PA, Antonio MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009; 5: 989-1004.
7. Yukhanyan Liana, Freynhofer Matthias K, Siller-Matula Jolanta, Schrör Karsten, Huber Kurt. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost. 2011; 105(suppl 1): S55-S59.
8. Campo G, Fileti L, Valgimigli M, et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis. 2010; 30: 319-331.
9. Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet. 2009; 374: 952-953.
10. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. 2010; 103: 151-159.
11. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss- of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2008; 108: 2244-2247.
12. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84: 891-896.
13. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005; 31: 174-183.
14. Fontana P, Hulot JS, De Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost. 2007; 5: 2153-2155.
15. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008; 101: 1088-1093.
16. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/ A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high- risk vascular patients. Pharmacogenet Genomics. 2007; 17: 1057-1064.
17. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P- glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006; 80: 486-501.
18. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "Boxed Warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010; 122: 537-557.
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999; 354(9193): 1896-1900.
20. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol. 2010; 56(20): 1630-1636.
21. Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010; 8(1): 43-53.
22. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008; 1(6): 620-627.
23. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121(4): 512-518.
24. Hwang SJ, Jeong YH, Kim IS, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010; 3(5): 450-459.
25. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec; 5(12): 2429-2436.
26. Mega JL, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study [abstract 1017-69, American College of Cardiology 57th Annual Scientific Session, Chicago, IL, March 29-April 1, 2008]. J Am Coll Cardiol. 2008; 51(suppl A 10): A178-A235. http://dx.doi.org/10.1016/j.jacc.2008.02.007.
27. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302: 849-857.
28. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4): 354-362.
29. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010; 363(18): 1704-1714.
30. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008; 72: 1165-1169.
31. Simon T, Verstuyft C, Mary-Krause M, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-375.
32. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug- eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51: 1925-1934.
33. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373: 309-317.
34. Wallentin L, James S, Storey RF, et al. PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic sub-study of the PLATO trial. Lancet. 2010; 376(9749): 1320-1328.
35. Bhatt DL, Paré G, Eikelboom JW, et al. On behalf of the CHARISMA Investigators. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012 Mar 26. http://dx.doi.org/10.1093/eurheartj/ehs059.
36. Anderson JL, Mower CP, Horne BD, et al. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel (abstr). J Am Coll Cardiol. 2009; 53(suppl A): A27.
37. Worrall A, Armesilla A, Norell M, et al. The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the VerifyNow P2Y12 near-patient testing device in patients undergoing coronary angiography (abstr). Eur Heart J. 2009; 30(suppl): 327.
38. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009; 30: 916-922.
39. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009; 103: 806-811.
40. Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol. 2011; 57(2): 194-201.
41. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010; 376(9749): 1312-1319.
42. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011; 11(3): 199-206.
43. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep. 2011; 38(3): 1697-1702.
44. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010; 56(2): 134-143.
45. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304(16): 1821-1830.
46. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126-2130.
47. Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010 Sep 14; 56(12): 919-933.
48. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16; 305(11): 1097-1105.
49. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol. 2012 Apr 9. http://dx.doi.org/10.1016/j.jacc.2012.02.026 [Epub ahead of print].
50. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007 Aug; 154(2): 221-231.
51. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol. 2007 Jan; 2(1): 93-109.
52. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm; Accessed 12. 03. 10.